These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 34579102)

  • 1. Casein Glycomacropeptide: An Alternative Protein Substitute in Tyrosinemia Type I.
    Daly A; Evans S; Pinto A; Ashmore C; MacDonald A
    Nutrients; 2021 Sep; 13(9):. PubMed ID: 34579102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycomacropeptide in children with phenylketonuria: does its phenylalanine content affect blood phenylalanine control?
    Daly A; Evans S; Chahal S; Santra S; MacDonald A
    J Hum Nutr Diet; 2017 Aug; 30(4):515-523. PubMed ID: 28111827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effect of Glycomacropeptide versus Amino Acids on Phenylalanine and Tyrosine Variability over 24 Hours in Children with PKU: A Randomized Controlled Trial.
    Daly A; Evans S; Chahal S; Santra S; Pinto A; Gingell C; Rocha JC; van Spronsen F; Jackson R; MacDonald A
    Nutrients; 2019 Feb; 11(3):. PubMed ID: 30823411
    [No Abstract]   [Full Text] [Related]  

  • 4. Glycomacropeptide: long-term use and impact on blood phenylalanine, growth and nutritional status in children with PKU.
    Daly A; Evans S; Chahal S; Santra S; Pinto A; Jackson R; Gingell C; Rocha J; Van Spronsen FJ; MacDonald A
    Orphanet J Rare Dis; 2019 Feb; 14(1):44. PubMed ID: 30770754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary Investigation to Review If a Glycomacropeptide Compared to L-Amino Acid Protein Substitute Alters the Pre- and Postprandial Amino Acid Profile in Children with Phenylketonuria.
    Daly A; Evans S; Pinto A; Jackson R; Ashmore C; Rocha JC; MacDonald A
    Nutrients; 2020 Aug; 12(8):. PubMed ID: 32823853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural Protein Tolerance and Metabolic Control in Patients with Hereditary Tyrosinaemia Type 1.
    Yilmaz O; Daly A; Pinto A; Ashmore C; Evans S; Gupte G; Santra S; Preece MA; Mckiernan P; Kitchen S; Ayhan NY; MacDonald A
    Nutrients; 2020 Apr; 12(4):. PubMed ID: 32325917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 12-month, longitudinal, intervention study examining a tablet protein substitute preparation in the management of tyrosinemia.
    Daly A; Evans S; Pinto A; Ashmore C; MacDonald A
    Mol Genet Metab Rep; 2024 Sep; 40():101119. PubMed ID: 39081551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth and Body Composition in PKU Children-A Three-Year Prospective Study Comparing the Effects of L-Amino Acid to Glycomacropeptide Protein Substitutes.
    Daly A; Högler W; Crabtree N; Shaw N; Evans S; Pinto A; Jackson R; Strauss BJ; Wilcox G; Rocha JC; Ashmore C; MacDonald A
    Nutrients; 2021 Apr; 13(4):. PubMed ID: 33923714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of casein glycomacropeptide versus free synthetic amino acids for early treatment of phenylketonuria in a mice model.
    Ahring KK; Dagnæs-Hansen F; Brüel A; Christensen M; Jensen E; Jensen TG; Johannsen M; Johansen KS; Lund AM; Madsen JG; Brøndum-Nielsen K; Pedersen M; Sørensen LK; Kjolby M; Møller LB
    PLoS One; 2022; 17(1):e0261150. PubMed ID: 35015767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nutritional status in patients with phenylketonuria using glycomacropeptide as their major protein source.
    Pinto A; Almeida MF; Ramos PC; Rocha S; Guimas A; Ribeiro R; Martins E; Bandeira A; MacDonald A; Rocha JC
    Eur J Clin Nutr; 2017 Oct; 71(10):1230-1234. PubMed ID: 28402322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of the Use of Glycomacropeptide on Satiety and Dietary Intake in Phenylketonuria.
    Daly A; Evans S; Pinto A; Jackson R; Ashmore C; Rocha JC; MacDonald A
    Nutrients; 2020 Sep; 12(9):. PubMed ID: 32899700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of paediatric PKU breath malodour, comparing glycomacropeptide with phenylalanine free L-amino acid supplements.
    Tiele A; Daly A; Hattersley J; Pinto A; Evans S; Ashmore C; MacDonald A; Covington JA
    J Breath Res; 2019 Oct; 14(1):016001. PubMed ID: 31476741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a New Glycomacropeptide-Based Protein Substitute in Powdered and Liquid Format in Patients with PKU.
    Delsoglio M; Capener R; MacDonald A; Daly A; Ashmore C; Ellerton C; Donald S; Gaff L; VanDorp L; Skeath R; Newby C; Dunning G; Dale C; Hunjan I; White L; Allen H; Hubbard GP; Stratton RJ
    Nutrients; 2023 Aug; 15(16):. PubMed ID: 37630769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Three-Year Longitudinal Study Comparing Bone Mass, Density, and Geometry Measured by DXA, pQCT, and Bone Turnover Markers in Children with PKU Taking L-Amino Acid or Glycomacropeptide Protein Substitutes.
    Daly A; Högler W; Crabtree N; Shaw N; Evans S; Pinto A; Jackson R; Ashmore C; Rocha JC; Strauss BJ; Wilcox G; Fraser WD; Tang JCY; MacDonald A
    Nutrients; 2021 Jun; 13(6):. PubMed ID: 34204378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Casein glycomacropeptide in phenylketonuria: does it bring clinical benefit?
    Daly A; Ilgaz F; Pinto A; MacDonald A
    Curr Opin Clin Nutr Metab Care; 2024 Jan; 27(1):31-39. PubMed ID: 38085662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective.
    Pena MJ; Pinto A; de Almeida MF; de Sousa Barbosa C; Ramos PC; Rocha S; Guimas A; Ribeiro R; Martins E; Bandeira A; Dias CC; MacDonald A; Borges N; Rocha JC
    Orphanet J Rare Dis; 2021 Feb; 16(1):84. PubMed ID: 33581730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Use of Glycomacropeptide in Patients with Phenylketonuria: A Systematic Review and Meta-Analysis.
    Pena MJ; Pinto A; Daly A; MacDonald A; Azevedo L; Rocha JC; Borges N
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30453665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
    Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
    J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of a New 'Mix-In' Style Glycomacropeptide-Based Protein Substitute for Food and Drinks in Patients with Phenylketonuria and Tyrosinemia.
    Delsoglio M; Capener R; MacDonald A; Daly A; Ashmore C; Donald S; Gaff L; VanDorp L; Skeath R; Ellerton C; Newby C; Dunning G; Dale C; Hunjan I; White L; Allen H; Hubbard GP; Stratton RJ
    Nutrients; 2023 Aug; 15(16):. PubMed ID: 37630788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycomacropeptide for nutritional management of phenylketonuria: a randomized, controlled, crossover trial.
    Ney DM; Stroup BM; Clayton MK; Murali SG; Rice GM; Rohr F; Levy HL
    Am J Clin Nutr; 2016 Aug; 104(2):334-45. PubMed ID: 27413125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.